SEEL Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Seelos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.35 |
| 52 Week High | US$698.88 |
| 52 Week Low | US$0.20 |
| Beta | 1.94 |
| 11 Month Change | -68.64% |
| 3 Month Change | -93.29% |
| 1 Year Change | -99.95% |
| 33 Year Change | -100.00% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Seelos: Data This Year Is Critical
Oct 04Seelos wins Parkinson’s research grant for gene therapy program
Aug 24Seelos: FDA Action Makes It Highly Attractive
Dec 22Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains
Oct 01We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely
Aug 18
Seelos: Superior Data, But Early Stage
Jun 09Shareholder Returns
| SEEL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -49.4% | -5.3% | -1.2% |
| 1Y | -99.9% | 8.7% | 30.4% |
Return vs Industry: SEEL underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: SEEL underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| SEEL volatility | |
|---|---|
| SEEL Average Weekly Movement | 29.7% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SEEL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SEEL's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 8 | Raj Mehra | seelostherapeutics.com |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Seelos Therapeutics, Inc. Fundamentals Summary
| SEEL fundamental statistics | |
|---|---|
| Market cap | US$154.49k |
| Earnings (TTM) | US$4.09m |
| Revenue (TTM) | US$2.01m |
0.0x
P/E Ratio0.1x
P/S RatioIs SEEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEEL income statement (TTM) | |
|---|---|
| Revenue | US$2.01m |
| Cost of Revenue | US$20.45m |
| Gross Profit | -US$18.43m |
| Other Expenses | -US$22.53m |
| Earnings | US$4.09m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.38 |
| Gross Margin | -915.34% |
| Net Profit Margin | 203.13% |
| Debt/Equity Ratio | -35.9% |
How did SEEL perform over the long term?
See historical performance and comparison